🔗 Share this article

The initial novel therapies for gonorrhoea in a generation are being viewed as a "significant breakthrough" in the battle against superbug strains of the bacteria, according to health experts.

A Worldwide Challenge

Gonorrhoea infections are on the rise globally, with figures suggesting in excess of 82 million infections per year. Particularly high rates are seen in the African continent and countries within the WHO's Western Pacific region, which encompasses Mongolia and China to New Zealand. Within England, cases have reached a record high, while infection numbers across Europe in 2023 were three times higher compared to those in 2014.

“The approval of fresh medications for gonorrhoea is an critical and opportune development in the context of increasing worldwide cases, increasing antimicrobial resistance and the highly restricted therapeutic options at this time.”

Public health authorities are particularly alarmed about the increase in drug-resistant strains. The WHO has classified it as a "critical concern". Ongoing monitoring revealed that the effectiveness of key first-line drugs like cefixime and ceftriaxone increased dramatically between 2022 and 2024.

A Pair of Novel Therapies Receive Clearance

Zoliflodacin, alternatively called Nuzolvence, was cleared by the American regulatory agency in recent days for combating gonorrhoea. This STI can lead to serious health problems, including the inability to conceive. Researchers hope that focused deployment of this new drug will help hinder the development of resistance.

Another new antibiotic, originating from the drugmaker GlaxoSmithKline, gained clearance in close succession. This medication, which is additionally indicated for urinary tract infections, was proven in research to be able to combat antibiotic-resistant forms of the gonorrhoea bacteria.

A Unique Partnership

This new treatment was the result of a unique collaborative effort for medication research. The non-profit organisation Global Antibiotic Research & Development Partnership collaborated with the pharmaceutical company Innoviva to bring it to fruition.

“This approval marks a major breakthrough in the therapy of highly resistant gonorrhoea, which up to this point has been evolving faster than our drug pipeline.”

Clinical Trial Results and Worldwide Availability

As per results published in a prominent scientific publication, zoliflodacin cured the vast majority of cases of the STI. This places it at an comparable level with the existing first-line therapy, which involves two antibiotics. The study enrolled over 900 patients from various regions including the United States, Thailand, South Africa, and European nations.

Through the arrangement of its development partnership, the non-profit has the ability to license and sell the drug in numerous developing nations.

Medical professionals directly involved have voiced optimism. Access to a one-pill regimen like this is hailed as a "critical tool" for public health efforts. This is deemed vital to reduce the burden of the illness for individuals and to stop the proliferation of untreatable gonorrhoea globally.